Bifidobacterium lactis Bb12 enhances intestinal antibody response in formula-fed infants: a randomized, double-blind, controlled trial - PubMed (original) (raw)
Randomized Controlled Trial
. 2012 Jan;36(1 Suppl):106S-17S.
doi: 10.1177/0148607111430817.
Affiliations
- PMID: 22237870
- DOI: 10.1177/0148607111430817
Randomized Controlled Trial
Bifidobacterium lactis Bb12 enhances intestinal antibody response in formula-fed infants: a randomized, double-blind, controlled trial
Hannah D Holscher et al. JPEN J Parenter Enteral Nutr. 2012 Jan.
Abstract
Background: Addition of probiotics to infant formula may positively affect immune function in nonexclusively breastfed infants. This study aimed to investigate the effect of infant starter formula containing the probiotic Bifidobacterium animalis subspecies lactis (Bb12) on intestinal immunity and inflammation.
Methods: Six-week-old healthy, full-term infants (n = 172) were enrolled in a prospective, randomized, double-blind, controlled clinical trial with 2 groups studied in parallel to a breastfed comparison group. Formula-fed (FF) infants were randomized to partially hydrolyzed whey formula (CON) or the same formula containing 10(6) colony-forming units (CFU) Bb12/g (PRO) for 6 weeks. Fecal secretory IgA (sIgA), calprotectin, lactate, and stool pH were assessed at baseline, 2 weeks, and 6 weeks. Anti-poliovirus-specific IgA and anti-rotavirus-specific IgA were assessed at 2 and 6 weeks.
Results: Among vaginally delivered FF infants, PRO consumption increased (P < .05) fecal sIgA compared to CON. Anti-poliovirus-specific IgA concentration increased (P < .05) in all infants consuming PRO, whereas anti-rotavirus-specific IgA tended to increase (P = .056) with PRO consumption in cesarean-delivered infants. Anthropometrics and tolerance did not differ significantly between FF infants.
Conclusions: Infants consuming formula with Bb12 produced feces with detectable presence of Bb12 and augmented sIgA concentration. Furthermore, cesarean-delivered infants consuming Bb12 had heightened immune response, as evidenced by increased anti-rotavirus- and anti-poliovirus-specific IgA following immunization. These results demonstrate that negative immune-related effects of not breastfeeding and cesarean delivery can be mitigated by including Bb12 in infant formula, thereby providing infants a safe, dietary, immune-modulating bacterial introduction.
Similar articles
- Pre-, pro-, syn-, and Postbiotics in Infant Formulas: What Are the Immune Benefits for Infants?
Lemoine A, Tounian P, Adel-Patient K, Thomas M. Lemoine A, et al. Nutrients. 2023 Feb 28;15(5):1231. doi: 10.3390/nu15051231. Nutrients. 2023. PMID: 36904230 Free PMC article. Review. - Effects of Bifidobacterium lactis Bb12 supplementation on body weight, fecal pH, acetate, lactate, calprotectin, and IgA in preterm infants.
Mohan R, Koebnick C, Schildt J, Mueller M, Radke M, Blaut M. Mohan R, et al. Pediatr Res. 2008 Oct;64(4):418-22. doi: 10.1203/PDR.0b013e318181b7fa. Pediatr Res. 2008. PMID: 18552710 Clinical Trial. - Faecal SIgA secretion in infants fed on pre- or probiotic infant formula.
Bakker-Zierikzee AM, Tol EA, Kroes H, Alles MS, Kok FJ, Bindels JG. Bakker-Zierikzee AM, et al. Pediatr Allergy Immunol. 2006 Mar;17(2):134-40. doi: 10.1111/j.1399-3038.2005.00370.x. Pediatr Allergy Immunol. 2006. PMID: 16618363 Clinical Trial. - Effects of prebiotic-containing infant formula on gastrointestinal tolerance and fecal microbiota in a randomized controlled trial.
Holscher HD, Faust KL, Czerkies LA, Litov R, Ziegler EE, Lessin H, Hatch T, Sun S, Tappenden KA. Holscher HD, et al. JPEN J Parenter Enteral Nutr. 2012 Jan;36(1 Suppl):95S-105S. doi: 10.1177/0148607111430087. JPEN J Parenter Enteral Nutr. 2012. PMID: 22237884 Clinical Trial. - Growth of infants fed formula supplemented with Bifidobacterium lactis Bb12 or Lactobacillus GG: a systematic review of randomized controlled trials.
Szajewska H, Chmielewska A. Szajewska H, et al. BMC Pediatr. 2013 Nov 12;13:185. doi: 10.1186/1471-2431-13-185. BMC Pediatr. 2013. PMID: 24215626 Free PMC article. Review.
Cited by
- Effectiveness and safety study of formula containing probiotics, prebiotics, synbiotics on fullterm infants' growth - a systematic review and meta-analysis of randomized controlled study.
Qian J, Fang Z, Chang S, Zeng Z, Zhang J. Qian J, et al. Eur J Clin Nutr. 2024 Oct 24. doi: 10.1038/s41430-024-01506-9. Online ahead of print. Eur J Clin Nutr. 2024. PMID: 39448812 Review. - Overview of anti-viral effects of probiotics via immune cells in pre-, mid- and post-SARS-CoV2 era.
Kanauchi O, Low ZX, Jounai K, Tsuji R, AbuBakar S. Kanauchi O, et al. Front Immunol. 2023 Dec 5;14:1280680. doi: 10.3389/fimmu.2023.1280680. eCollection 2023. Front Immunol. 2023. PMID: 38116008 Free PMC article. Review. - Development of the Neonatal Intestinal Barrier, Microbiome, and Susceptibility to NEC.
Golubkova A, Hunter CJ. Golubkova A, et al. Microorganisms. 2023 May 9;11(5):1247. doi: 10.3390/microorganisms11051247. Microorganisms. 2023. PMID: 37317221 Free PMC article. Review. - Effect of Lacticaseibacillus paracasei N1115 on Immunomodulatory and Gut Microbial Composition in Young Children: A Randomized, Placebo-Controlled Study.
Li P, Ren Z, Zhou J, Zhao A, Wang S, Xun Y, Jiang H, Wang P, Yuan Q, Zhang Y. Li P, et al. Nutrients. 2023 Apr 19;15(8):1970. doi: 10.3390/nu15081970. Nutrients. 2023. PMID: 37111189 Free PMC article. Clinical Trial. - Pre-, pro-, syn-, and Postbiotics in Infant Formulas: What Are the Immune Benefits for Infants?
Lemoine A, Tounian P, Adel-Patient K, Thomas M. Lemoine A, et al. Nutrients. 2023 Feb 28;15(5):1231. doi: 10.3390/nu15051231. Nutrients. 2023. PMID: 36904230 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous